IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 18, 2024 -- Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV) is less likely with an increasing social vulnerability index (SVI) and Black race, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 16 to 19 in Los Angeles.
Zainab Albar, M.B.B.S., Ph.D., from Case Western Reserve University in Cleveland, and colleagues analyzed data from patients with acute respiratory infections and examined the connection of SVI and race with vaccination rates for influenza, SARS-CoV-2, and RSV. The cohort included a diverse population of 341,029 individuals (81 percent White).
The researchers found that vaccination rates decreased as the SVI quartile increased, especially among Black individuals. In addition, with higher SVI quartiles, there were increases in emergency visits for acute respiratory infections and decreases in primary care visits. As the SVI quartile increased, the likelihood of vaccination decreased, especially among Black people; Black individuals had lower odds of receiving a flu vaccine in all SVI quartiles. The odds of receiving SARS-CoV-2 and RSV vaccines were also lower for Black versus White individuals in all SVI quartiles.
"Disparities this vast are not to be overlooked -- they require multifaceted interventions that meet people where they are socially and increase access to essential preventive measures," coauthor Elie Saade, M.D., M.P.H., from the University Hospitals of Cleveland, said in a statement.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Further Support and Information on COVID-19
Read this next
Azelastine Nasal Spray Reduces Risk for SARS-CoV-2 Infection
FRIDAY, Sept. 5, 2025 -- Azelastine nasal spray is associated with a reduced risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study...
COVID-19 Tied to Higher Risk for Inflammatory Diseases of the Airways
THURSDAY, Aug. 28, 2025 -- People who have had COVID-19 have an increased risk for developing certain new-onset type 2 inflammatory diseases of the airways, while receipt of a...
29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season
MONDAY, Aug. 25, 2025 -- Overall, 29 percent of infants born during October 2023 to March 2024 were immunized against respiratory syncytial virus (RSV) during the 2023 to 2024...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.